within Pharmacolibrary.Drugs.ATC.A;

model A10AD05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 1.2 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 0.2 / 1000000,
    adminCount     = 1,
    Vd             = 0.00011999999999999999,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Insulin aspart is a fast-acting human insulin analog used to improve glycemic control in adults and children with diabetes mellitus. It is approved for use in many countries and is commonly administered by subcutaneous injection immediately before meals.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic model parameters reported for healthy adult volunteers following single subcutaneous injection.</p><h4>References</h4><ol><li><p>Mathiesen, ER, et al., &amp; Damm, P (2023). Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open‑label, multinational, randomised, controlled, non-inferiority trial. <i>The lancet. Diabetes &amp; endocrinology</i> 11(2) 86–95. DOI:<a href=&quot;https://doi.org/10.1016/S2213-8587(22)00307-2&quot;>10.1016/S2213-8587(22)00307-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36623517/&quot;>https://pubmed.ncbi.nlm.nih.gov/36623517</a></p></li><li><p>Rasmussen, CH, et al., &amp; Colding-Jørgensen, M (2014). Insulin aspart pharmacokinetics: an assessment of its variability and underlying mechanisms. <i>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</i> 62 65–75. DOI:<a href=&quot;https://doi.org/10.1016/j.ejps.2014.05.010&quot;>10.1016/j.ejps.2014.05.010</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24878388/&quot;>https://pubmed.ncbi.nlm.nih.gov/24878388</a></p></li><li><p>Rosinha, P, et al., &amp; Cardoso, MH (2022). Faster Insulin Aspart for Continuous Subcutaneous Insulin Infusion: Is It Worth It?. <i>Cureus</i> 14(8) e28422–None. DOI:<a href=&quot;https://doi.org/10.7759/cureus.28422&quot;>10.7759/cureus.28422</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36176818/&quot;>https://pubmed.ncbi.nlm.nih.gov/36176818</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A10AD05;
